Anthera Pharmaceuticals Cash and ST Investments:
24.75M for Dec. 31, 2012Anthera Pharmaceuticals Historical Cash and ST Investments Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 24.75M |
| June 30, 2012 | 22.89M |
| March 31, 2012 | 44.03M |
| Dec. 31, 2011 | 67.37M |
| Sept. 30, 2011 | 93.26M |
| June 30, 2011 | 112.10M |
| March 31, 2011 | 78.54M |
| Dec. 31, 2010 | 63.38M |
| Sept. 30, 2010 | 73.09M |
| June 30, 2010 | 51.04M |
| March 31, 2010 | 56.66M |
| Dec. 31, 2009 | 3.803M |
| Sept. 30, 2009 | 7.584M |
| June 30, 2009 | 1.291M |
| Dec. 31, 2008 | 7.895M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and short term investments are considered very liquid assets. For instance, if a company needs immediate liquidity, cash and short term investments can be be quickly used. Cash and short term investments are frequently used in liquidity ratios.
Learn More
ANTH Cash and ST Investments Benchmarks
| Companies | |
|---|---|
| GlaxoSmithKline | 5.950B |
| Pfizer | |
| Tetraphase Pharmaceuticals | 9.079M |
ANTH Cash and ST Investments Rankings
| Overall |
63rd percentile 2901 of 8002 |
| Sector |
45th percentile 355 of 650 in Healthcare |
| Industry |
61st percentile 20 of 52 in Drug Manufacturers - Major |
ANTH Cash and ST Investments Range, Past 5 Years
| Minimum | 1.291M | Jun 2009 |
| Maximum | 112.10M | Jun 2011 |
| Average | 47.18M |
